ATE471722T1 - Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen - Google Patents

Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen

Info

Publication number
ATE471722T1
ATE471722T1 AT04720472T AT04720472T ATE471722T1 AT E471722 T1 ATE471722 T1 AT E471722T1 AT 04720472 T AT04720472 T AT 04720472T AT 04720472 T AT04720472 T AT 04720472T AT E471722 T1 ATE471722 T1 AT E471722T1
Authority
AT
Austria
Prior art keywords
compositions
apelin
angiogenesis
regulating angiogenesis
methods
Prior art date
Application number
AT04720472T
Other languages
English (en)
Inventor
Paul Krieg
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Application granted granted Critical
Publication of ATE471722T1 publication Critical patent/ATE471722T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04720472T 2003-03-12 2004-03-12 Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen ATE471722T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45403403P 2003-03-12 2003-03-12
US52815503P 2003-12-09 2003-12-09
PCT/US2004/007738 WO2004081198A2 (en) 2003-03-12 2004-03-12 Methods for modulating angiogenesis with apelin compositions

Publications (1)

Publication Number Publication Date
ATE471722T1 true ATE471722T1 (de) 2010-07-15

Family

ID=32994538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720472T ATE471722T1 (de) 2003-03-12 2004-03-12 Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen

Country Status (6)

Country Link
US (1) US7736646B2 (de)
EP (1) EP1613348B1 (de)
JP (1) JP2006523209A (de)
AT (1) ATE471722T1 (de)
DE (1) DE602004027798D1 (de)
WO (1) WO2004081198A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019193A1 (ja) * 2004-08-20 2006-02-23 Takeda Pharmaceutical Company Limited 阻害剤・促進剤の用途
JP2008013436A (ja) * 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US20080026986A1 (en) * 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
US20100028256A1 (en) * 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis
WO2009033819A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008303922A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent
WO2011056073A2 (en) * 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
SI3045183T1 (sl) * 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
KR101327663B1 (ko) 2011-10-07 2013-11-14 중앙대학교 산학협력단 안지오제닌의 신규 용도
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9353163B2 (en) 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
US11104730B2 (en) * 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
WO2015077491A1 (en) 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
AU2015233370A1 (en) * 2014-03-20 2016-09-22 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting Apelin / APJ / GP130 signaling for treating cancer
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
MX2018013546A (es) * 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
EA201992630A1 (ru) * 2017-05-06 2020-04-29 Ридженерон Фармасьютикалз, Инк. Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
GB201805675D0 (en) 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5496698A (en) 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
KR20010033601A (ko) 1997-12-24 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 폴리펩티드, 그의 제법 및 용도
JP4429410B2 (ja) * 1997-12-24 2010-03-10 武田薬品工業株式会社 新規生理活性物質、その製造法および用途
AU1797100A (en) * 1998-12-11 2000-07-03 Takeda Chemical Industries Ltd. Process for producing apelin
JP2002544128A (ja) 1999-05-06 2002-12-24 ファイザー・プロダクツ・インク 置換ベンゾラクタム化合物
WO2000068244A1 (en) * 1999-05-12 2000-11-16 Smithkline Beecham Corporation 7tm receptor mouse apj
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US20100028256A1 (en) * 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis

Also Published As

Publication number Publication date
JP2006523209A (ja) 2006-10-12
US7736646B2 (en) 2010-06-15
WO2004081198A2 (en) 2004-09-23
EP1613348A2 (de) 2006-01-11
DE602004027798D1 (de) 2010-08-05
EP1613348A4 (de) 2006-07-05
US20040219152A1 (en) 2004-11-04
WO2004081198A3 (en) 2004-12-16
EP1613348B1 (de) 2010-06-23

Similar Documents

Publication Publication Date Title
ATE471722T1 (de) Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
WO2006023893A3 (en) Methods for modulating angiogenesis and apoptosis with apelin compositions
ATE454161T1 (de) Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
ATE554087T1 (de) Neue kinaseinhibitoren
ATE369144T1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
WO2005005462A3 (en) Blys antagonists and uses thereof
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60007095D1 (de) Calanolide zur hemmung von btk
EA200600440A1 (ru) 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
WO2006076736A3 (en) Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
DE602005026169D1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE311388T1 (de) Pyrimidotriazine als phosphataseinhibitoren
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
ATE506370T1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties